

# BACITRACIN OPHTHALMIC OINTMENT USP


Active against **88% to 99%** of identified key gram-positive isolates from conjunctivitis and blepharitis in *in vitro* studies<sup>1</sup>

91%  
Staphylococcus aureus  
(n=55)<sup>1</sup>

88%  
Coagulase-negative  
Staphylococcus  
(n=199)<sup>1</sup>

97%  
Other gram-positives  
(n=101)<sup>1</sup>

99%  
Streptococcus pneumoniae  
(n=259)<sup>1</sup>



In Vitro Susceptibility Data Provided Through the University of Pittsburgh Medical Center.  
In Vitro Data Should Not Be Considered Representative of Clinical Efficacy<sup>1</sup>

## Established therapeutic utility in blepharitis, conjunctivitis, and other superficial ocular infections caused by Bacitracin-susceptible organisms

- **Excellent safety profile**—low incidence of adverse events<sup>2</sup>
- Ointment provides **long-lasting ocular surface contact time** and **greater bioavailability**<sup>3</sup>
- **Anti-infective efficacy** in a lubricating base<sup>2</sup>
- **Flexible dosing**—1 to 3 times daily<sup>2</sup>
- **Tier 1 pharmacy benefit status**—on most insurance plans<sup>4</sup>

### Indication

Bacitracin Ophthalmic Ointment is indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

### Important Safety Information

This product should not be used in patients with a history of hypersensitivity to Bacitracin. Bacitracin Ophthalmic Ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic. There is a low incidence of allergenicity exhibited by Bacitracin. If such reactions do occur, therapy should be discontinued.

See below for full prescribing information.

NDC	Size	Case Pack
0574-4022-35	3.5 g	144 / 12

©2022, Padagis LLC 0S4-www04-ver01.01 Perrigo® is a registered trademark owned by L. Perrigo Company and is used under license.

Bioequivalency Rating: **RLD**

**References:** 1. Antibiotic susceptibility: conjunctivitis and blepharitis. University of Pittsburgh Medical Center, Charles T. Campbell Eye Microbiology Lab Web site. <http://eyemicrobiology.upmc.com/AntibioticSusceptibilities/Conjunctivitis.htm> Accessed November 21, 2022. 2. Bacitracin Ophthalmic Ointment [package insert]. Minneapolis, MN: Data on file. Padagis US LLC; November 2022. 3. Hecht G. Ophthalmic preparations. In: Gennaro AR, ed. Remington: the Science and Practice of Pharmacy. 20th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000. 4. Data on file. Padagis US LLC.



# Bacitracin Ophthalmic Ointment USP

**STERILE**      **Rx Only**

**DESCRIPTION:** Each gram of ointment contains 500 units of Bacitracin in a low melting special base containing White Petrolatum and Mineral Oil.

**CLINICAL PHARMACOLOGY:** The antibiotic, Bacitracin, exerts a profound action against many gram-positive pathogens, including the common Streptococci and Staphylococci. It is also destructive for certain gram-negative organisms. It is ineffective against fungi.

**INDICATIONS AND USAGE:** For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

**CONTRAINDICATIONS:** This product should not be used in patients with a history of hypersensitivity to Bacitracin.

**PRECAUTIONS:** Bacitracin ophthalmic ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic. The prolonged use of antibiotic containing preparations may result in overgrowth of nonsusceptible organisms particularly fungi. If new infections develop during treatment appropriate antibiotic or chemotherapy should be instituted.

**ADVERSE REACTIONS:** Bacitracin has such a low incidence of allergenicity that for all practical purposes side reactions are practically non-existent. However, if such reaction should occur, therapy should be discontinued.

To report SUSPECTED ADVERSE REACTIONS, contact Padagis at 1-866-634-9120 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**DOSAGE AND ADMINISTRATION:** The ointment should be applied directly into the conjunctival sac 1 to 3 times daily. In blepharitis all scales and crusts should be carefully removed and the ointment then spread uniformly over the lid margins. Patients should be instructed to take appropriate measures to avoid gross contamination of the ointment when applying the ointment directly to the infected eye.

## **HOW SUPPLIED:**

NDC 0574-4022-35 3.5 g (1/8 oz.) sterile tamper evident tubes with ophthalmic tip.

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Manufactured For Padagis

Minneapolis, MN 55427

OS400 RC J1    Rev 08-13 A

R0813

Ini0813